Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma is a phase 1/2, interventional study registered as NCT07463599 by HonorHealth Research Institute, with a registry enrolment figure of 126 participants, started 2026-02-17 and due to reach its primary completion in 2029-01. Interventions recorded: Tegavivint. Conditions listed: Metastatic Colorectal Carcinoma (mCRC); Colorectal Cancer (CRC); Adenomatous Polyposis Coli (APC) Gene Mutation; Catenin Beta-1 (CTNNB1) Gene Mutation. Primary outcome: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; Maximum Tolerated Dose (MTD)/Administered Dose. Colorectal eligibility wording from the registry: "Histologically and/or cytologically documented metastatic colorectal adenocarcinoma (all other histological types are excluded)". Sites: United States. No results are recorded here; the registry entry is the source.